214 related articles for article (PubMed ID: 36889810)
1. Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.
Bhave P; Hong A; Lo SN; Johnson R; Mangana J; Johnson DB; Dulgar O; Eroglu Z; Yeoh HL; Haydon A; Lodde GC; Livingstone E; Khattak A; Kähler K; Hausschild A; McArthur GA; Menzies AM; Long G; Wang W; Carlino MS
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36889810
[TBL] [Abstract][Full Text] [Related]
2. Treatment management for
Haist M; Stege H; Rogall F; Tan Y; von Wasielewski I; Klespe KC; Meier F; Mohr P; Kähler KC; Weichenthal M; Hauschild A; Schadendorf D; Ugurel S; Lodde G; Zimmer L; Gutzmer R; Debus D; Schilling B; Kreuter A; Ulrich J; Meiss F; Herbst R; Forschner A; Leiter U; Pfoehler C; Kaatz M; Ziller F; Hassel JC; Tronnier M; Sachse M; Dippel E; Terheyden P; Berking C; Heppt MV; Kiecker F; Haferkamp S; Gebhardt C; Simon JC; Grabbe S; Loquai C
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730278
[TBL] [Abstract][Full Text] [Related]
3. Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2).
Broman KK; Hughes T; Dossett L; Sun J; Kirichenko D; Carr MJ; Sharma A; Bartlett EK; Nijhuis AAG; Thompson JF; Hieken TJ; Kottschade L; Downs J; Gyorki DE; Stahlie E; van Akkooi A; Ollila DW; Frank J; Song Y; Karakousis G; Moncrieff M; Nobes J; Vetto J; Han D; Farma JM; Deneve JL; Fleming MD; Perez MC; Lowe MC; Olofsson Bagge R; Mattsson J; Lee AY; Berman RS; Chai H; Kroon HM; Teras J; Teras RM; Farrow NE; Beasley G; Hui JYC; Been L; Kruijff S; Kim Y; Naqvi SMH; Sarnaik AA; Sondak VK; Zager JS
Cancer; 2021 Jul; 127(13):2251-2261. PubMed ID: 33826754
[TBL] [Abstract][Full Text] [Related]
4. Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.
Eroglu Z; Broman KK; Thompson JF; Nijhuis A; Hieken TJ; Kottschade L; Farma JM; Hotz M; Deneve J; Fleming M; Bartlett EK; Sharma A; Dossett L; Hughes T; Gyorki DE; Downs J; Karakousis G; Song Y; Lee A; Berman RS; van Akkooi A; Stahlie E; Han D; Vetto J; Beasley G; Farrow NE; Hui JYC; Moncrieff M; Nobes J; Baecher K; Perez M; Lowe M; Ollila DW; Collichio FA; Bagge RO; Mattsson J; Kroon HM; Chai H; Teras J; Sun J; Carr MJ; Tandon A; Babacan NA; Kim Y; Naqvi M; Zager J; Khushalani NI
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002183
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
Taylor AM; McKeown J; Dimitriou F; Jacques SK; Zimmer L; Allayous C; Yeoh HL; Haydon A; Ressler JM; Galea C; Woodford R; Kahler K; Hauschild A; Festino L; Hoeller C; Schwarze JK; Neyns B; Wicky A; Michielin O; Placzke J; Rutkowski P; Johnson DB; Lebbe C; Dummer R; Ascierto PA; Lo S; Long GV; Carlino MS; Menzies AM
Eur J Cancer; 2024 Mar; 199():113561. PubMed ID: 38278009
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era.
Straker RJ; Song Y; Sun J; Shannon AB; Cohen LS; Muradova E; Daou H; Krause K; Li S; Frederick DT; Rhodin KE; Brizel DM; Boland GM; Beasley GM; Wuthrick EJ; Sondak VK; Zager JS; Lin A; Lukens JN; Karakousis GC
Ann Surg Oncol; 2021 Jul; 28(7):3512-3521. PubMed ID: 33230747
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Radiation Does Not Affect Locoregional Control Following Resection of Melanoma Satellitosis or In-Transit Disease.
Yaney AC; Rossfeld KK; Wu TC; Agnese DM; Terando AM; Wuthrick EJ; Howard JH
Am Surg; 2023 Apr; 89(4):850-857. PubMed ID: 34645291
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Eggermont AM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Konto C; Hoos A; de Pril V; Gurunath RK; de Schaetzen G; Suciu S; Testori A
Lancet Oncol; 2015 May; 16(5):522-30. PubMed ID: 25840693
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Therapy is Effective for Melanoma Patients with a Positive Sentinel Lymph Node Biopsy Who Forego Completion Lymphadenectomy.
Farrow NE; Raman V; Williams TP; Nguyen KY; Tyler DS; Beasley GM
Ann Surg Oncol; 2020 Dec; 27(13):5121-5125. PubMed ID: 32314157
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant nodal field radiation in resected Stage III melanoma: A single-centre retrospective study in Christchurch, New Zealand.
Leong TW; McCook G; Frampton CM; Robinson BA; James ML
J Med Imaging Radiat Oncol; 2022 Oct; 66(7):1003-1013. PubMed ID: 35642730
[TBL] [Abstract][Full Text] [Related]
11. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy
Owen CN; Shoushtari AN; Chauhan D; Palmieri DJ; Lee B; Rohaan MW; Mangana J; Atkinson V; Zaman F; Young A; Hoeller C; Hersey P; Dummer R; Khattak MA; Millward M; Patel SP; Haydon A; Johnson DB; Lo S; Blank CU; Sandhu S; Carlino MS; Larkin JMG; Menzies AM; Long GV
Ann Oncol; 2020 Aug; 31(8):1075-1082. PubMed ID: 32387454
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.
Li T; Jia DD; Teng LS
Invest New Drugs; 2020 Oct; 38(5):1334-1341. PubMed ID: 32072356
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Livingstone E; Zimmer L; Hassel JC; Fluck M; Eigentler TK; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kiecker F; Dippel E; Roesch A; Ziemer M; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2022 Oct; 400(10358):1117-1129. PubMed ID: 36099927
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of adjuvant programmed cell death 1 (PD-1) monoclonal antibody immunotherapy in Chinese patients with resected stage Ⅱ-Ⅲ melanoma].
Ren ZG; Xu Y; Hua ZZ; Mo ZY; Wang LW; Shi GB; Liu WL; Sun W; Zheng BQ; Wang CM; Jin YJ; Chen Y
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):973-980. PubMed ID: 37968084
[No Abstract] [Full Text] [Related]
15. Practice-Changing Developments in Stage III Melanoma: Surgery, Adjuvant Targeted Therapy, and Immunotherapy.
Kudchadkar RR; Michielin O; van Akkooi ACJ
Am Soc Clin Oncol Educ Book; 2018 May; 38():759-762. PubMed ID: 30231370
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study.
Jia DD; Xu Y; Li T; Yang JL; Chen Y; Li T
Invest New Drugs; 2023 Jun; 41(3):431-437. PubMed ID: 37093349
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.
Henderson MA; Burmeister BH; Ainslie J; Fisher R; Di Iulio J; Smithers BM; Hong A; Shannon K; Scolyer RA; Carruthers S; Coventry BJ; Babington S; Duprat J; Hoekstra HJ; Thompson JF
Lancet Oncol; 2015 Sep; 16(9):1049-1060. PubMed ID: 26206146
[TBL] [Abstract][Full Text] [Related]
18. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
20. Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease.
Uppal A; Stern S; Thompson JF; Foshag L; Mizzollo N; Nieweg OE; Hoekstra HJ; Roses DF; Sondak VK; Kashani-Sabet M; Coventry BJ; Cochran AJ; Fujita M; Sim-Shin M; Elashoff D; Elashoff RM; Faries MB
Ann Surg Oncol; 2020 Jun; 27(6):1970-1977. PubMed ID: 31863416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
